Assessment of Expected Out-of-Pocket Spending for Rheumatoid Arthritis Biologics Among Patients Enrolled in Medicare Part D, 2010-2019

IMPORTANCE: The closure of the Medicare Part D coverage gap from 2010 to 2019 was intended to help decrease out-of-pocket costs for beneficiaries, especially those taking high-cost drugs. However, yearly increases in list prices and the introduction of newer and more expensive drugs may have limited...

Descripción completa

Detalles Bibliográficos
Autores principales: Erath, Alexandra, Dusetzina, Stacie B.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Medical Association 2020
Materias:
Original Investigation
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7186858/
https://www.ncbi.nlm.nih.gov/pubmed/32338754
http://dx.doi.org/10.1001/jamanetworkopen.2020.3969

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7186858/
https://www.ncbi.nlm.nih.gov/pubmed/32338754
http://dx.doi.org/10.1001/jamanetworkopen.2020.3969

Ejemplares similares